RxSight Outlook Is Cloudy Even After Revised Guidance Resets Floor -- Market Talk

Dow Jones

Jul 09, 2025

0915 ET - RxSight's latest update leaves more questions than answers, JPMorgan analysts say in a research note. The ophthalmic medical-device company on Tuesday guided for a 2Q revenue decline and lowered full-year revenue guidance. The analysts note a few factors for the shortfall, including softness in cataract volumes and increased competition in the premium intraocular lens space. "It's difficult to underwrite the outlook beyond 2H25 even as the revised guidance sets a hopeful floor to grow off of," say the analysts. "We're reiterating our underweight rating as a result and expect RxSight to remain in the penalty box as it aims to both showcase stability in 2H25 and the ability to return to growth in 2026+." Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden)

(END) Dow Jones Newswires

July 09, 2025 09:15 ET (13:15 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2550658397"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550658397\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550658397?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550658397","market":"other","top_or_hot":-1,"title":"RxSight Outlook Is Cloudy Even After Revised Guidance Resets Floor -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0915 ET - RxSight's latest update leaves more questions than answers, JPMorgan analysts say in a research note. The ophthalmic medical-device company on Tuesday guided for a 2Q revenue decline and lowered full-year revenue guidance. The analysts note a few factors for the shortfall, including softness in cataract volumes and increased competition in the premium intraocular lens space. \"It's difficult to underwrite the outlook beyond 2H25 even as the revised guidance sets a hopeful floor to grow off of,\" say the analysts. \"We're reiterating our underweight rating as a result and expect RxSight to remain in the penalty box as it aims to both showcase stability in 2H25 and the ability to return to growth in 2026+.\" Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 09:15 ET (13:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RxSight Outlook Is Cloudy Even After Revised Guidance Resets Floor -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRxSight Outlook Is Cloudy Even After Revised Guidance Resets Floor -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-09 21:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0915 ET - RxSight's latest update leaves more questions than answers, JPMorgan analysts say in a research note. The ophthalmic medical-device company on Tuesday guided for a 2Q revenue decline and lowered full-year revenue guidance. The analysts note a few factors for the shortfall, including softness in cataract volumes and increased competition in the premium intraocular lens space. \"It's difficult to underwrite the outlook beyond 2H25 even as the revised guidance sets a hopeful floor to grow off of,\" say the analysts. \"We're reiterating our underweight rating as a result and expect RxSight to remain in the penalty box as it aims to both showcase stability in 2H25 and the ability to return to growth in 2026+.\" Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 09:15 ET (13:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550658397","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550658397","pubTimestamp":1752066900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0915 ET - RxSight's latest update leaves more questions than answers, JPMorgan analysts say in a research note. The ophthalmic medical-device company on Tuesday guided for a 2Q revenue decline and lowered full-year revenue guidance. The analysts note a few factors for the shortfall, including softness in cataract volumes and increased competition in the premium intraocular lens space. \"It's difficult to underwrite the outlook beyond 2H25 even as the revised guidance sets a hopeful floor to grow off of,\" say the analysts. \"We're reiterating our underweight rating as a result and expect RxSight to remain in the penalty box as it aims to both showcase stability in 2H25 and the ability to return to growth in 2026+.\" Shares dive 49% to $6.50 in premarket trading. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4198":"医疗保健用品","RXST":"RxSIGHT, INC."},"translate_title":"即使修订后的指导重置下限，RxSight的前景仍阴云密布——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXST":0.9},"content_text":"0915 ET - RxSight's latest update leaves more questions than answers, JPMorgan analysts say in a research note. The ophthalmic medical-device company on Tuesday guided for a 2Q revenue decline and lowered full-year revenue guidance. The analysts note a few factors for the shortfall, including softness in cataract volumes and increased competition in the premium intraocular lens space. \"It's difficult to underwrite the outlook beyond 2H25 even as the revised guidance sets a hopeful floor to grow off of,\" say the analysts. \"We're reiterating our underweight rating as a result and expect RxSight to remain in the penalty box as it aims to both showcase stability in 2H25 and the ability to return to growth in 2026+.\" Shares dive 49% to $6.50 in premarket trading. (denny.jacob@wsj.com; @pennedbyden) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2025 09:15 ET (13:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}